Literature DB >> 10879616

Liver and brain mucormycosis in a diabetic patient type II successfully treated with liposomial amphotericin B.

G Tsaousis1, A Koutsouri, C Gatsiou, O Paniara, C Peppas, G Chalevelakis.   

Abstract

A case of liver and brain mucormycosis in a 73-y-old diabetic patient is described. The patient presented with fever and a moderate, tender hepatomegaly and a C/T scan examination of the abdomen and brain showed multiple hepatic and cerebral nodular lesions. The largest of the liver lesions was aspirated and broad hyphae of mucor were demonstrated in the purulent material obtained. The patient was treated successfully (for 40 d) with intravenous liposomal amphotericin B and then with itraconazole for 3 months. To our knowledge, this is the first case of a diabetic patient with both liver and brain mucormycosis who has been treated successfully.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879616     DOI: 10.1080/00365540050166090

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Hepatic mucormycosis mimicking hilar cholangiocarcinoma: a case report and literature review.

Authors:  Ke-Wei Li; Tian-Fu Wen; Gan-Di Li
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

2.  Mucormycosis: ten-year experience at a tertiary-care center in Greece.

Authors:  G Petrikkos; A Skiada; H Sambatakou; A Toskas; G Vaiopoulos; M Giannopoulou; N Katsilambros
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-06       Impact factor: 3.267

3.  "An unusual presentation of colonic mucormycosis mimicking carcinoma colon- a surgeon's perspective".

Authors:  Prasanna Kumar Debata; Sangram Keshari Panda; Atmaranjan Dash; Ramakant Mohanty; Biranchi Narayan Mallick; Debabrata Tadu; Vivek G Nath; Abhinash Sahoo
Journal:  Int J Surg Case Rep       Date:  2015-02-18

Review 4.  Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.

Authors:  P Monika; M N Chandraprabha
Journal:  Mol Biol Rep       Date:  2022-02-02       Impact factor: 2.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.